The Impact of Therapeutic Antibodies on the Management of Digestive Diseases

History, Current Practice, and Future Directions

Mark (Anthony) Sofia, David T. Rubin

Research output: Contribution to journalEditorial

9 Citations (Scopus)

Abstract

The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn’s disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

Original languageEnglish (US)
Pages (from-to)833-842
Number of pages10
JournalDigestive diseases and sciences
Volume62
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Disease Management
History
Antibodies
Inflammatory Bowel Diseases
Therapeutics
Ulcerative Colitis
Crohn Disease
Virulence
Pharmacokinetics
Direction compound
Cytokines
Pharmaceutical Preparations
Infliximab

Keywords

  • Adalimumab
  • Inflammatory bowel disease
  • Infliximab
  • Therapeutic antibodies
  • Therapeutic drug monitoring
  • Tumor necrosis factor alpha

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases : History, Current Practice, and Future Directions. / Sofia, Mark (Anthony); Rubin, David T.

In: Digestive diseases and sciences, Vol. 62, No. 4, 01.04.2017, p. 833-842.

Research output: Contribution to journalEditorial

@article{a6c0cde0d61a49569f64cea5a1d0647d,
title = "The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions",
abstract = "The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn’s disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.",
keywords = "Adalimumab, Inflammatory bowel disease, Infliximab, Therapeutic antibodies, Therapeutic drug monitoring, Tumor necrosis factor alpha",
author = "Sofia, {Mark (Anthony)} and Rubin, {David T.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s10620-017-4479-0",
language = "English (US)",
volume = "62",
pages = "833--842",
journal = "American Journal of Digestive Diseases and Nutrition",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "4",

}

TY - JOUR

T1 - The Impact of Therapeutic Antibodies on the Management of Digestive Diseases

T2 - History, Current Practice, and Future Directions

AU - Sofia, Mark (Anthony)

AU - Rubin, David T.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn’s disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

AB - The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn’s disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

KW - Adalimumab

KW - Inflammatory bowel disease

KW - Infliximab

KW - Therapeutic antibodies

KW - Therapeutic drug monitoring

KW - Tumor necrosis factor alpha

UR - http://www.scopus.com/inward/record.url?scp=85012874237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012874237&partnerID=8YFLogxK

U2 - 10.1007/s10620-017-4479-0

DO - 10.1007/s10620-017-4479-0

M3 - Editorial

VL - 62

SP - 833

EP - 842

JO - American Journal of Digestive Diseases and Nutrition

JF - American Journal of Digestive Diseases and Nutrition

SN - 0163-2116

IS - 4

ER -